Skip to content

Cardiological Drug Classes And Falls in Older Adults

Heart Failure Pharmacological Treatments and Falls in Older Adults: A Disproportionality Analysis of the WHO Pharmacovigilance Database

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07150754
Enrollment
100000
Registered
2025-09-02
Start date
2024-11-02
Completion date
2025-07-01
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fall, Heart Failure

Keywords

Heart failure, Falls, Pharmacological treatments

Brief summary

Heat failure is a fast gowing health issue with a rising incidence in older adults. Recommendations have recently been published to treat heart failure, but most clinical trials leading to these recommendations tended to exclude older adults. Older adults are at higher risk of falls and severe consequences of falls. All heart failure treatments are at risk of causing a fall through different mechanisms. Based on the World Health Organization global database, the main objective of this study is to investigate the association between heart failure pharmacological treatments and the report of a fall in the database. A disproportionality analysis will be performed. It will aim to assess whether some classes of heart failure drugs, and within these classes some individual drugs, are associated with a report of a fall. A sensibilty analysis will also be performed. It will aim to examine the association between takien a heart failure pharmacological treatment, with a heat failure indication and/or a loop diuretic, and the report of a fall.

Interventions

DRUGHeart failure pharmacological treatments

Identify a positive signal for fall with one or more of the recommended pharmacological treatments for heart failure

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum

Inclusion criteria

* Age 65 years of older

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frame
Report of a fall with a recommended pharmacological treatment for heart failure02/11/2024

Secondary

MeasureTime frameDescription
Sensibility analysis02/11/2024Reports of falls with one or more of the respective drug classes that also had either furosemide prescription and/or heart failure as indication

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026